News : edluar

Uppsala, Sweden, July 25 2011 – The insomnia drug Sublinox (Edluar) has been approved in Canada. Meda and its partner Valeant expect to begin the launch in the fourth quarter 2011.

Sublinox will be marketed by the joint venture between Meda and Valeant, Meda Valeant Pharma Canada Inc. Meda has global rights to the drug and markets it in the USA since 2009 under the name Edluar. Orexo, who has developed the drug, is...

Uppsala, February 17, 2010

Orexo AB (publ) –
Year-end Report January–December 2009



Key events during the year
• Net revenues totaled MSEK 236.1 (233.3).
• The loss after tax was MSEK 98.1 (loss: 103.1).
• The loss per share amounted to a loss of SEK 4.32 (loss: 4.77).
• Cash and cash equivalents at year-end totaled MSEK 87.4 (188.2).
• Abstral was launched in UK, Germany, France, Spain and Greece.
• In March,...

Uppsala, November 10, 2009

Orexo AB (publ) – Interim report January-September 2009


Key events during the period
• Net revenues amounted to MSEK 208.2 (141.2).
• The loss after tax was MSEK 40.1 (loss: 88,6).
• The loss per share was SEK 1.78 (loss: 4.10).
• Cash and cash equivalents at the end of the quarter totaled MSEK 107.1 (195.7).
• In March, the US Food and Drug Administration (FDA) approved Orexo’s Edluar...

Key events during the period
• Net revenues amounted to MSEK 144.6 (80.2).
• The loss after tax was MSEK 30.5 (loss: 90.5).
• The loss per share was SEK 1.38 (loss: 4.19).
• Cash and cash equivalents at the end of the quarter amounted to MSEK 137.2 (247.1).
• The US Food and Drug Administration (FDA) approved Orexo’s EdluarTM product for the short-term treatment of insomnia. The approval meant that Orexo received a...

Uppsala, Sweden, 18 August 2009 - Orexo (STO: ORX) confirms that Meda (STO: MEDA A) has initiated the launch the drug EdluarTM in the United States of America. The launch follows the US Food and Drug Administration’s (FDA) approval in March this year of EdluarTM 5 mg and 10 mg sublingual tablets for the short-term treatment of insomnia characterized by difficulties with sleep initiation.

Meda acquired exclusive...

• Meda expects to launch Edluar in the USA during 2nd half of 2009
• Orexo receives a milestone payment of USD 5 million from Meda
• Orexo’s second major product approval in 12 months

Orexo (NASDAQ-OMX:ORX) today announces that the US Food and Drug Administration (FDA) has approved Edluar (formerly Sublinox) 5 mg and 10 mg sublingual tablets for the short-term treatment of insomnia characterized by difficulties...